KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Cash & Equivalents (2016 - 2025)

Cvs Health's Cash & Equivalents history spans 17 years, with the latest figure at $8.5 billion for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 1.55% year-over-year to $8.5 billion, compared with a TTM value of $8.5 billion through Dec 2025, down 1.55%, and an annual FY2025 reading of $8.5 billion, down 1.55% over the prior year.
  • Cash & Equivalents for Q4 2025 was $8.5 billion at Cvs Health, down from $9.1 billion in the prior quarter.
  • The five-year high for Cash & Equivalents was $17.2 billion in Q3 2022, with the low at $5.6 billion in Q1 2021.
  • Average Cash & Equivalents over 5 years is $10.5 billion, with a median of $9.8 billion recorded in 2021.
  • Year-over-year, Cash & Equivalents plummeted 52.12% in 2021 and then soared 75.02% in 2022.
  • Tracing CVS's Cash & Equivalents over 5 years: stood at $9.4 billion in 2021, then surged by 37.6% to $12.9 billion in 2022, then crashed by 36.69% to $8.2 billion in 2023, then increased by 4.76% to $8.6 billion in 2024, then dropped by 1.55% to $8.5 billion in 2025.
  • Per Business Quant, the three most recent readings for CVS's Cash & Equivalents are $8.5 billion (Q4 2025), $9.1 billion (Q3 2025), and $11.8 billion (Q2 2025).